These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28291641)

  • 1. Long-term treatment with interferon alfa for myeloproliferative neoplasms.
    Kiladjian JJ
    Lancet Haematol; 2017 Apr; 4(4):e150-e151. PubMed ID: 28291641
    [No Abstract]   [Full Text] [Related]  

  • 2. [Interferon-alfa in the treatment of myeloproliferative diseases].
    Adam Z
    Vnitr Lek; 1993 Dec; 39(12):1210-8. PubMed ID: 8310673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome.
    Zhou L; Fu W; Yuan Z; Hou J
    Leuk Res; 2010 Nov; 34(11):e306-7. PubMed ID: 20650528
    [No Abstract]   [Full Text] [Related]  

  • 4. Recombinant alpha 2 interferon in the treatment of chronic myeloproliferative disorders.
    Bonaccorso R; Teresi M; Gebbia V; Tambone Reyes M; Tinnirello D; Di Marco P; Citarrella P; Mansueto S
    J Chemother; 1989 Jul; 1(4 Suppl):1266-8. PubMed ID: 16312860
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.
    Forsyth CJ; Chan WH; Grigg AP; Cook NC; Lane SW; Burbury KL; Perkins AC; Ross DM
    Intern Med J; 2019 Aug; 49(8):948-954. PubMed ID: 30411442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and myeloproliferative neoplasms: some considerations.
    Kamaz B; Mullally A
    Leukemia; 2021 Jan; 35(1):279-281. PubMed ID: 33106624
    [No Abstract]   [Full Text] [Related]  

  • 8. [Status and perspectives on chronic myeloproliferative neoplasm treatment].
    Ocias LF; Holmström MO; Riley CH; Andersen CL; Rønnov-Jessen D; Starklint J; Frederiksen M; Steffensen MS; Bjerrum OW; Farmer S; Mourits-Andersen T; Hasselbalch HC; Larsen TS
    Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
    Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC
    PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
    Appelbaum FR
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
    Kiladjian JJ; Chomienne C; Fenaux P
    Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
    Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
    Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.
    Kiladjian JJ; Giraudier S; Cassinat B
    Leukemia; 2016 Apr; 30(4):776-81. PubMed ID: 26601783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to the treatment of thrombocytosis.
    Fruchtman S
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):92-3. PubMed ID: 16224383
    [No Abstract]   [Full Text] [Related]  

  • 16. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
    Hansen IO; Sørensen AL; Hasselbalch HC
    Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
    Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
    Petit J; Callís M; Domingo Albós A; Fernández de Sevilla A; Besses C; Martí JM
    Med Clin (Barc); 1993 Nov; 101(16):601-3. PubMed ID: 8271861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relief of itch associated with myeloproliferative disease by alpha-interferon.
    Flecknoe-Brown S
    Aust N Z J Med; 1991 Feb; 21(1):81. PubMed ID: 2036085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.